Back Back
Cell No. : Cell Name
RCB0755 : OMC-3  update : 2022/08/18
CommentMucinous cystadenocarcinoma. Said CA125,CA19-9 (+).
Comment from the depositor
Terms and conditionsA prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
approver's address
Osaka Medical and Pharmaceutical University
2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan
Dr.YAMADA Takashi
Fax. +81-72-684-6513
Order Form Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Yamada, Takashi
Originator Yamada, Takashi
Year of deposit 1992
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 58 years
Tissue ovary
Disease name mucinous cystadenocarcinoma
Classification cancer
Year of origin 1984
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_3354
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium HamF12 + 10% NBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 4 split
SC frequency Subculture : once/2-3 weeks, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
Chromosome mode 41-88(50) : /42(8),43(15),44(8),82(1),83(2)/
STR(human) OK
deposit info
lot info
Reference information Reference 10
User's Publication 13

To topTop
888  Ueda M, Toji E, Noda S.  Germ line and somatic mutations of BRAF V599E in ovarian carcinoma  Int J Gynecol Cancer  2007  17(4):794-7  PubMed ID: 17309670   DOI: 10.1111/j.1525-1438.2006.00853.x
885  Ueda M, Hung YC, Chen JT, Chiou SH, Huang HH, Lin TY, Terai Y, Chow KC.  Infection of human papillomavirus and overexpression of dihydrodiol dehydrogenase in uterine cervical cancer  Gynecol Oncol  2006  102(2):173-81  PubMed ID: 16427687   DOI: 10.1016/j.ygyno.2005.12.009
886  Ueda M, Hung YC, Terai Y, Kanda K, Kanemura M, Futakuchi H, Yamaguchi H, Akise D, Yasuda M, Ueki M.  Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas  Clin Cancer Res  2005  11(9):3225-32  PubMed ID: 15867217   DOI: 10.1158/1078-0432.CCR-04-1148
887  Tumor angiogenesis and molecular target therapy in ovarian carcinomas  Tumor angiogenesis and molecular target therapy in ovarian carcinomas  Hum Cell  2005  18(1):1-16  PubMed ID: 16130895   DOI: 10.1111/j.1749-0774.2005.tb00052.x
80  Ueda M, Ueki M, Terai Y, Ueki K, Kumagai K, Fujii H, Yoshizawa K, Nakajima M.  Biological implications of growth factors on the mechanism of invasion in gynecological tumor cells  Gynecol Obstet Invest  1999  48(3):221-8  PubMed ID: 10545752   DOI: 10.1159/000010160
79  Ueda M, Fujii H, Yoshizawa K, Kumagai K, Ueki K, Terai Y, Yanagihara T, Ueki M.  Effects of sex steroids and growth factors on invasive activity and 5'-deoxy-5-fluorouridine sensitivity in ovarian adenocarcinoma OMC-3 cells  Jpn J Cancer Res  1998  89(12):1334-42  PubMed ID: 10081495   DOI: 10.1111/j.1349-7006.1998.tb00531.x
81  Effects of EGF and TGF-alpha on invasion and proteinase expression of uterine cervical adenocarcinoma OMC-4 cells  Effects of EGF and TGF-alpha on invasion and proteinase expression of uterine cervical adenocarcinoma OMC-4 cells  Invasion Metastasis  1998  18(4):176-83  PubMed ID: 10640903   DOI: 10.1159/000024510
82  Ueda M, Fujii H, Yoshizawa K, Abe F, Ueki M.  Effects of sex steroids and growth factors on migration and invasion of endometrial adenocarcinoma SNG-M cells in vitro  Jpn J Cancer Res  1996  87(5):524-33  PubMed ID: 8641991   DOI: 10.1111/j.1349-7006.1996.tb00255.x
1794  Yamada T, Ueda M, Otsuki Y, Ueki M, Sugimoto O  Establishment and characterization of a cell line (OMC-3) originating from a human mucinous cystadenocarcinoma of the ovary.  Gynecol Oncol  1991  40:118-28  PubMed ID: 2010102   DOI: 10.1016/0090-8258(91)90102-b
78  Ueda M, Seiki Y, Yamada T, Okamoto Y, Tsurunaga T, Iwai E, Ueki M, Sugimoto O.  In vitro studies on the expression of c-myc oncogene product in gynecological cultured cancer cells  Nihon Sanka Fujinka Gakkai Zasshi  1991  43(11):1489-95  PubMed ID: 1940543  

To topTop
User's Publication
11872  Koh I, Nosaka S, Sekine M, Sugimoto J, Hirata E, Kudo Y.  Regulation of REG4 Expression and Prediction of 5-Fluorouracil Sensitivity by CDX2 in Ovarian Mucinous Carcinoma.  Cancer Genomics Proteomics  2019    PubMed ID: 31659102   DOI: 10.21873/cgp.20151
9647  Koh I, Hinoi T, Sentani K, Hirata E, Nosaka S, Niitsu H, Miguchi M, Adachi T, Yasui W, Ohdan H, Kudo Y.  Regulation of multidrug resistance 1 expression by CDX2 in ovarian mucinous adenocarcinoma.  Cancer Med  2016  5:1546-55  PubMed ID: 27060927   DOI: 10.1002/cam4.697
13459  Inaba K, Oda K, Aoki K, Sone K, Ikeda Y, Miyasaka A, Kashiyama T, Fukuda T, Makii C, Arimoto T, Wada-Hiraike O, Kawana K, Yano T, Osuga Y, Fujii T.  Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging  Oncotarget  2016  7(20):29577-91.  PubMed ID: 27102436   DOI: 10.18632/oncotarget.8807
7132  Zhao S, Ma Y, Huang X.  Trefoil factor 1 elevates the malignant phenotype of mucinous ovarian cancer cell through Wnt/β-catenin signaling.  Int J Clin Exp Pathol  2015  8:10412-9  PubMed ID: 26617749  
14956  Takata A, Terauchi M, Hiramitsu S, Uno M, Wakana K, Kubota T.  Dkk-3 induces apoptosis through mitochondrial and Fas death receptor pathways in human mucinous ovarian cancer cells  Int J Gynecol Cancer  2015  25(3):372-9  PubMed ID: 25514350   DOI: 10.1097/IGC.0000000000000340
13692  Uno M, Saitoh Y, Mochida K, Tsuruyama E, Kiyono T, Imoto I, Inazawa J, Yuasa Y, Kubota T, Yamaoka S.  NF-κB inducing kinase, a central signaling component of the non-canonical pathway of NF-κB, contributes to ovarian cancer progression  PLoS One  2014  9(2):e88347.  PubMed ID: 24533079   DOI: 10.1371/journal.pone.0088347
15560  Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, Hayashi S, Sasano H, Yaegashi N.  Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma.  Cancer Sci  2008  99:2365-72  PubMed ID: 19032364   DOI: 10.1111/j.1349-7006.2008.00988.x
2934  Akahira, Jun-ichi, Sugihashi, Youko, Suzuki, Takashi, Ito, Kiyoshi, Niikura, Hitoshi, Moriya, Takuya, Nitta, Makoto, Okamura, Hitoshi, Inoue, Satoshi, Sasano, Hironobu, Okamura, Kunihiro, Yaegashi, Nobuo  Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation.  Clin Cancer Res  2004  10:2687-93  PubMed ID: 15102672   DOI: 10.1158/1078-0432.ccr-03-0510
6401  Tsuchiya Y, Nakajima M, Itoh S, Iwanari M, Yokoi T.  Expression of aryl hydrocarbon receptor repressor in normal human tissues and inducibility by polycyclic aromatic hydrocarbons in human tumor-derived cell lines.  Toxicol Sci  2003  72(2):253-9  PubMed ID: 12655030   DOI: 10.1093/toxsci/kfg022
6402  Nakajima M, Iwanari M, Yokoi T.  Effects of histone deacetylation and DNA methylation on the constitutive and TCDD-inducible expressions of the human CYP1 family in MCF-7 and HeLa cells.  Toxicol Lett  2003  144(2):247-56  PubMed ID: 12927368   DOI: 10.1016/s0378-4274(03)00216-9
6404  Tsuchiya Y, Nakajima M, Yokoi T.  Critical enhancer region to which AhR/ARNT and Sp1 bind in the human CYP1B1 gene.  J Biochem  2003  133(5):583-92  PubMed ID: 12801909   DOI: 10.1093/jb/mvg075
6399  Iwanari M, Nakajima M, Kizu R, Hayakawa K, Yokoi T.  Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences.  Arch Toxicol  2002  76(5-6):287-98  PubMed ID: 12107646   DOI: 10.1007/s00204-002-0340-z
6162  Yamada A, Kawano K, Harashima N, Niiya F, Nagai K, Kobayashi T, Mine T, Ushijima K, Nishida T, Itoh K.  Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer.  Cancer Immunol Immunother  1999  48(2-3):147-52  PubMed ID: 10414469   DOI: 10.1007/s002620050559

Back Back Return Top Page